Latest News and Press Releases

ATHLONE, Ireland, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting...

ATHLONE, Ireland, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of...

ATHLONE, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting...

COACT-1 and COACT-2 Phase 3 clinical trials for COGENZIA did not achieve statistical significance in improving clinical cure in diabetic foot infections (DFI)New Drug Application (NDA) for XARACOLL...

ATHLONE, Ireland, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting...

ATHLONE, Ireland, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of...

ATHLONE, Ireland, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of...

ATHLONE, Ireland, July 06, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL) a global, specialty pharmaceutical and medical device company with late stage development programs targeting...

ATHLONE, Ireland, June 23, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of...

ATHLONE, Ireland, June 16, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL) a global, specialty pharmaceutical and medical device company with late stage development programs targeting...